Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

BACKGROUND: Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non–small-cell lung cancers, representing 2 to 7% of such tumors. We explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clinical trial of crizotin...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Kwak, Eunice L., Bang, Yung-Jue, Camidge, D. Ross, Shaw, Alice T., Solomon, Benjamin, Maki, Robert G., Ou, Sai-Hong I., Dezube, Bruce J., Jänne, Pasi A., Costa, Daniel B., Varella-Garcia, Marileila, Kim, Woo-Ho, Lynch, Thomas J., Fidias, Panos, Stubbs, Hannah, Engelman, Jeffrey A., Sequist, Lecia V., Tan, WeiWei, Gandhi, Leena, Mino-Kenudson, Mari, Wei, Greg C., Shreeve, S. Martin, Ratain, Mark J., Settleman, Jeffrey, Christensen, James G., Haber, Daniel A., Wilner, Keith, Salgia, Ravi, Shapiro, Geoffrey I., Clark, Jeffrey W., Iafrate, A. John
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2010
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3014291/
https://ncbi.nlm.nih.gov/pubmed/20979469
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1006448
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk